Showing 2051-2060 of 5909 results for "".
- Tarsus Pharmaceuticals Presents Results of Atlas Study Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-presents-results-of-atlas-study-demonstrating-the-functional-and-psychosocial-impact-of-demodex-blepharitis/2479161/Tarsus Pharmaceuticals announced data from its Demodex blepharitis clinical program presented at the virtual Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. Tarsus’ lead product candidate, TP-03, is a topical ophthalmic formulation of lotilaner, a well-characteriz
- Hoya Vision Care Releases Results of 3-Year MiYOSMART Spectacle Lens Follow-up Studyhttps://modernod.com/news/hoya-vision-care-releases-results-of-3-year-miyosmart-spectacle-lens-follow-up-study/2479124/Hoya Vision Care shared the results of a 3-year follow-up clinical study on its MiYOSMART spectacle lens with patented Defocus Incorporated Multiple Segments (D.I.M.S.) Technology after releasing the information at the recent European Academy of Optometry and Optics (EAOO) ’21 conference. T
- Essilor Launches Crizal Rock No-Glare Lenseshttps://modernod.com/news/essilor-launches-crizal-rock-no-glare-lenses/2479069/The latest Crizal No-Glare lens innovation, Crizal Rock, is designed to help eye care professionals ensure their patients’ eyewear is protected from eye wiping and other common wearer habits. Launching today, the Crizal Rock lenses are 3 times more scratch-resistant than entry-level Crizal produc
- Essilor to Present New Results for its Stellest Lens for Children With Myopiahttps://modernod.com/news/essilor-to-present-new-results-for-its-stellest-lens-for-children-with-myopia/2479062/Essilor will unveil pivotal 2-year clinical trial results of its Stellest lens for myopia. The 2-year results demonstrate that Essilor Stellest lenses slow down myopia progression by 67% on average, when compared to single vision lenses, when worn at least 12 hours a day,1 according to
- J&J Vision Announces Collaboration with Menicon to Bring Forward Contact Lenses for Childrenhttps://modernod.com/news/jj-vision-announces-collaboration-with-menicon-to-bring-forward-contact-lenses-for-children/2479057/Johnson & Johnson Vision announced a global strategic collaboration with Menicon, a manufacturer of contact lenses. As part of the collaboration, Menicon will develop and manufacture the contact lenses to help manage the progression of myopia in children. Johnson & Johnson Vision will foc
- Jasmine Pachnanda Named Senior Vice President for CEO Leadership Alliance; Will Lead SoCal AI Initiativehttps://modernod.com/news/jasmine-pachnanda-named-senior-vice-president-for-ceo-leadership-alliance-will-lead-socal-ai-initiative/2479012/The CEO Leadership Alliance – Orange County (CLA-OC) has named Jasmine Pachnanda as Senior Vice President. Ms. Pachnanda will work with a range of partners and stakeholders, harnessing efforts to grow and demonstrate Southern California’s emerging leadership as a worldwide center for
- HK Scientist Develops Retinal Scan Technology to Identify Early Childhood Autismhttps://modernod.com/news/hk-scientist-develops-retinal-scan-technology-to-identify-early-childhood-autism/2478987/A Hong Kong scientist has developed a method to use machine learning and artificial intelligence to scan retinas of children as young as six to detect early autism or the risk of autism and hopes to develop a commercial product this year, according to a Reuters
- Visus Therapeutics Announces FDA Acceptance of IND to Proceed With Clinical Development of Presbyopia-Correcting Eye Drophttps://modernod.com/news/visus-therapeutics-announces-fda-acceptance-of-ind-for-presbyopia-correcting-eye-drop/2478973/Visus Therapeutics announced that the FDA has accepted the company’s investigational new drug application (IND) to proceed with the clinical development program for Brimochol, the company’s lead investigational asset. Under this IND, Visus will initiate its planned phase 2 clinical trial in the U
- Johnson & Johnson Vision Introduces Acuvue Oasys Multifocal with Pupil Optimized Designhttps://modernod.com/news/johnson-johnson-vision-introduces-acuvue-oasys-multifocal-with-pupil-optimized-design/2478970/Johnson & Johnson Vision has introduced a new eye care option for patients with presbyopia: Acuvue Oasys Multifocal Contact Lenses with Pupil Optimized Design. The new lens is now available in the United States and Canada.
- NIH-Led Team Sets New Bar in Retinal Imaginghttps://modernod.com/news/nih-led-team-sets-new-bar-in-retinal-imaging/2478963/A team led by scientists at the National Eye Institute (NEI) has noninvasively visualized the light-sensing cells in the back of the eye, known as photoreceptors, in greater detail than ever before. Published in Optica, the researchers report how they improved imaging resolution by a thi